MA39717A - Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs - Google Patents
Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateursInfo
- Publication number
- MA39717A MA39717A MA039717A MA39717A MA39717A MA 39717 A MA39717 A MA 39717A MA 039717 A MA039717 A MA 039717A MA 39717 A MA39717 A MA 39717A MA 39717 A MA39717 A MA 39717A
- Authority
- MA
- Morocco
- Prior art keywords
- cell
- methods
- regulatory
- increasing
- compositions
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 2
- 239000012636 effector Substances 0.000 title abstract 2
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne des procédés pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs. L'invention concerne en outre à des méthodes de traitement, de protection contre, et d'induction d'une réponse immunitaire contre une tumeur, comprenant l'étape d'administration à un sujet d'une souche de
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461948453P | 2014-03-05 | 2014-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39717A true MA39717A (fr) | 2017-01-11 |
Family
ID=54055997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039717A MA39717A (fr) | 2014-03-05 | 2015-03-05 | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170080064A1 (fr) |
EP (1) | EP3113794A4 (fr) |
JP (1) | JP2017508797A (fr) |
KR (1) | KR20160132033A (fr) |
CN (1) | CN106413745A (fr) |
AU (1) | AU2015227163A1 (fr) |
BR (1) | BR112016020364A2 (fr) |
CA (1) | CA2941405A1 (fr) |
IL (1) | IL247458A0 (fr) |
MA (1) | MA39717A (fr) |
MX (1) | MX2016011537A (fr) |
RU (1) | RU2016138601A (fr) |
SG (1) | SG11201607213QA (fr) |
WO (1) | WO2015134722A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
CA2829960A1 (fr) | 2011-03-11 | 2012-09-20 | John Rothman | Adjuvants a base de listeria |
WO2013138337A1 (fr) | 2012-03-12 | 2013-09-19 | Advaxis | Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria |
CN106456726A (zh) | 2014-02-18 | 2017-02-22 | 阿德瓦希斯公司 | 生物标志物导向的多靶点免疫治疗 |
SG10202011841WA (en) | 2014-04-24 | 2021-01-28 | Advaxis Inc | Recombinant listeria vaccine strains and methods of producing the same |
KR20170068560A (ko) | 2014-10-14 | 2017-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 암 치료에서의 병용 요법 |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
WO2017062976A1 (fr) * | 2015-10-09 | 2017-04-13 | Global Biopharma, Inc. | Combinaison de vaccin anti-cancer |
TWI765875B (zh) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
KR20190082850A (ko) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법 |
EP3645039A4 (fr) * | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose |
EP3652318A1 (fr) | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Souches bactériennes immunostimulatrices modifiées et utilisations |
NZ762881A (en) | 2017-09-19 | 2024-03-22 | Advaxis Inc | Compositions and methods for lyophilization of bacteria or listeria strains |
EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
CN110408634B (zh) | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
BR112021000315A2 (pt) | 2018-07-11 | 2021-08-03 | Actym Therapeutics, Inc. | cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos |
WO2020047161A2 (fr) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Souches bactériennes immunostimulatrices modifiées et utilisations associées |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662396B2 (en) * | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US8906664B2 (en) * | 2004-08-13 | 2014-12-09 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
PT2403935T (pt) * | 2009-03-04 | 2017-09-22 | Univ Pennsylvania | Composições compreendendo fatores angiogénicos e metedos para a sua utilização |
US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
WO2013138337A1 (fr) * | 2012-03-12 | 2013-09-19 | Advaxis | Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria |
MX2016011114A (es) * | 2014-02-25 | 2017-02-20 | Advaxis Inc | Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. |
-
2015
- 2015-03-05 US US15/123,468 patent/US20170080064A1/en not_active Abandoned
- 2015-03-05 CA CA2941405A patent/CA2941405A1/fr not_active Abandoned
- 2015-03-05 AU AU2015227163A patent/AU2015227163A1/en not_active Abandoned
- 2015-03-05 CN CN201580011943.7A patent/CN106413745A/zh active Pending
- 2015-03-05 EP EP15758226.3A patent/EP3113794A4/fr not_active Withdrawn
- 2015-03-05 SG SG11201607213QA patent/SG11201607213QA/en unknown
- 2015-03-05 RU RU2016138601A patent/RU2016138601A/ru not_active Application Discontinuation
- 2015-03-05 JP JP2016573685A patent/JP2017508797A/ja active Pending
- 2015-03-05 WO PCT/US2015/018915 patent/WO2015134722A2/fr active Application Filing
- 2015-03-05 MX MX2016011537A patent/MX2016011537A/es unknown
- 2015-03-05 KR KR1020167025525A patent/KR20160132033A/ko unknown
- 2015-03-05 MA MA039717A patent/MA39717A/fr unknown
- 2015-03-05 BR BR112016020364-0A patent/BR112016020364A2/pt not_active Application Discontinuation
-
2016
- 2016-08-24 IL IL247458A patent/IL247458A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015227163A1 (en) | 2016-10-20 |
RU2016138601A (ru) | 2018-04-05 |
IL247458A0 (en) | 2016-11-30 |
MX2016011537A (es) | 2017-05-01 |
EP3113794A2 (fr) | 2017-01-11 |
BR112016020364A2 (pt) | 2018-01-16 |
KR20160132033A (ko) | 2016-11-16 |
CA2941405A1 (fr) | 2015-09-11 |
US20170080064A1 (en) | 2017-03-23 |
SG11201607213QA (en) | 2016-09-29 |
EP3113794A4 (fr) | 2017-09-06 |
CN106413745A (zh) | 2017-02-15 |
WO2015134722A2 (fr) | 2015-09-11 |
JP2017508797A (ja) | 2017-03-30 |
WO2015134722A3 (fr) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
MX2023008686A (es) | Polinucleotidos moduladores. | |
MA40061A (fr) | Compositions immunogènes à base de listeria pour provoquer des réponses anti-tumorales | |
MX2017000857A (es) | Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata. | |
WO2015168379A3 (fr) | Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses | |
MY193723A (en) | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 | |
EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
NZ731696A (en) | Method for treating cancer | |
EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MY191539A (en) | Streptococcal vaccine | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
MX2021007899A (es) | Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6. | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
MX2017008055A (es) | Vacunacion. | |
MX2019003069A (es) | Uso de pridopidina para tratar el sindrome de rett. |